Table 1.
Baseline characteristics
| Eyes (n) | 72 |
| Age (years) | 62.2±12.5 |
| Gender, n (%) | |
| Male | 46 (64) |
| Female | 26 (36) |
| Type of diabetes, n (%) | |
| Type 1 | 3 (4) |
| Type 2 | 69 (96) |
| Duration of diabetes (years) | 15.3±8.5 |
| Duration of DR (years) | 4.4±4.1 |
| NGSP HbA1c (%)* | 7.37±1.23 |
| IFCC HbA1c (mmol/mol)* | 57.0±13.4 |
| Diabetic nephropathy,† n (%) | |
| Stage 1 | 6 (8) |
| Stage 2 | 27 (38) |
| Stage 3 | 11 (15) |
| Stage 4 | 5 (7) |
| Stage 5 | 1 (1) |
| Unknown | 22 (31) |
| Lens status, n (%) | |
| Phakic | 52 (72) |
| Intraocular lens | 16 (22) |
| Unknown | 4 (6) |
| DR, n (%) | |
| No DR | 22 (31) |
| Mild NPDR | 9 (13) |
| Moderate NPDR | 13 (18) |
| Severe NPDR | 8 (11) |
| PDR | 17 (24) |
| Unknown | 3 (4) |
| LogMAR BCVA | 0.036±0.159 |
| Central retinal thickness (μm) | 260.9±35.4 |
| Macular volume (mm3) | 10.46±1.05 |
| mGCIPL thickness (μm) | 79.8±15.0 |
| History of PRP, n(%) | 18 (25) |
Data are provided as mean±SD or n (%).
*n=53.
†Classified according to Classification of Diabetic Nephropathy 2014, published in Clin Exp Nephrol (2015) 19:1–5.
BCVA, best-corrected visual acuity; DR, diabetic retinopathy; HbA1c, hemoglobin A1c; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; logMAR, logarithm of the minimal angle of resolution; mGCIPL, macular ganglion cell complex–inner plexiform layer; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy; PRP, panretinal photocoagulation.